original articlesgastrointestinal tumorsFinal results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
gastrointestinal tumors
Under an Elsevier user license
open archive
Key words
antibody
chemotherapy
FOLFIRI
metastatic colorectal cancer
panitumumab
Cited by (0)
Copyright © 2013 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.